EVIDENT
Financiado
Ebola Virus Disease correlates of protection determinants of outcome and cli...
Ebola Virus Disease correlates of protection determinants of outcome and clinical management
The Ebola virus disease (EVD) epidemic in West Africa is not under control. This proposal has immediate, mid-term and long-term objectives to combat the current and future EVD epidemics. Objectives with immediate impact are: (i) P...
The Ebola virus disease (EVD) epidemic in West Africa is not under control. This proposal has immediate, mid-term and long-term objectives to combat the current and future EVD epidemics. Objectives with immediate impact are: (i) Providing key information needed to implement efficient convalescent plasma treatment and a toolkit to determine the suitability of plasma for treatment; (ii) Providing key information needed to estimate the efficacy of experimental vaccines, including correlates of protection at T cell level; (iii) Improving supportive treatment of patients and reducing hospital case fatality rate by providing information on biomarkers and relevant co-infections; (iv) Monitoring development of mutations in Ebola virus (EBOV) genomes during the epidemic and enhancing our preparedness to determine the relevance of these changes in experimental systems; and (v) Protecting health care workers and communities by providing information on virus shedding in body fluids and estimation of infectiousness in various stages of EVD. Objectives with mid to long-term impact are: (i) Provide information on pathophysiological changes and immunological determinants to infer new immunotherapeutic strategies for treatment of EVD; and (ii) Strengthening cooperation of biosafety level 4 (BSL-4) facilities and building a pan-European research area in the field of highly pathogenic viruses as envisaged in the ‘European Research Infrastructure on Highly Pathogenic Agents’ project. The concept of EVIDENT is to scientifically exploit specimens collected from EVD patients during outbreak response and field research. We will use state-of-the-art methodologies within the EU BSL-4 facilities to gather new and outbreak-relevant knowledge on B and T cell immunology, biomarkers, virus evolution, virulence determinants, and transmission of EBOV. The consortium contributes to the outbreak response since March 2014 and is competent to implement a project in the outbreak area.
ver más
Duración del proyecto: 22 meses
Fecha Inicio: 2014-12-03
Fecha Fin: 2016-10-31
Fecha Fin: 2016-10-31
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2016-10-31
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
Presupuesto
El presupuesto total del proyecto asciende a
2M€
Líder del proyecto
BERNHARDNOCHTINSTITUT FUER TROPENMEDIZIN
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
406.94K€ |
Participante